Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc reported its financial results for the fourth quarter and full year 2025, detailing a net loss of $21.6 million and $244.1 million, respectively, and providing a financial guidance for 2026. The company highlighted advancements in its pipeline, including the initiation of Phase 3 clinical trials for prasinezumab and coramitug by its partners Roche and Novo Nordisk, respectively, and the progression of other partnered and proprietary programs. Prothena also discussed its cash position, expected net cash use for 2026, and the potential for a share redemption program.
RBC Capital Raises Price Target for Prothena Corp (PRTA) to $12.00 | PRTA Stock News
RBC Capital has raised its price target for Prothena Corp (PRTA) from $11.00 to $12.00, while maintaining a "Sector Perform" rating. This adjustment reflects an increase in valuation, consistent with other analyst updates for the biotechnology company. Prothena Corp focuses on developing therapeutics for neurodegenerative, rare, and peripheral amyloid diseases.
Prothena (NASDAQ:PRTA) Price Target Raised to $12.00
Royal Bank of Canada has increased its price target for Prothena (NASDAQ:PRTA) from $11.00 to $12.00, maintaining a "sector perform" rating and suggesting a potential upside of 36.92%. While analyst coverage is mixed, with an average "Hold" rating and a consensus price target of $22.00, Prothena recently reported beating EPS estimates despite minimal revenue. The company is a clinical-stage biotechnology firm focused on neurodegenerative diseases, with significant institutional ownership.
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
Prothena reported a Q4 2025 adjusted loss per share of 45 cents, meeting estimates, and revenues of $0.02 million, missing expectations. The company provided 2026 guidance, expecting net cash burn between $50 million-$55 million and potential milestone payments of up to $105 million from partners like Novo Nordisk and Bristol Myers Squibb. Prothena also highlighted progress in its pipeline, including late-stage studies for Parkinson's and ATTR amyloidosis with cardiomyopathy.
Prothena Corporation plc (NASDAQ:PRTA) Q4 2025 Earnings Call Transcript
Prothena Corporation plc discussed their Q4 2025 financial results and provided 2026 guidance, highlighting significant progress in their clinical pipeline with two partner programs, prasinezumab and coramitug, advancing into Phase III trials. The company also introduced its CYTOPE technology for targeting intracellular disease pathways and outlined strategic priorities for 2026, including capturing value from partnerships and potential share redemption. They also discussed progress on BMS-986446 for Alzheimer's and PRX019 for neurodegenerative diseases.
Prothena Corporation plc announced that the company has the potential to receive up to $105 million in cumulative clinical milestone payments by the end of 2026.
Prothena Corporation plc announced that it could receive up to $105 million in cumulative clinical milestone payments by the end of 2026. This potential funding is contingent on the clinical progress of key projects within its research and development pipeline. The announcement highlights the company's anticipated financial gains from its ongoing R&D efforts.
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
Prothena's stock has dropped 36.8% over the past year, largely due to pipeline setbacks, including the discontinuation of birtamimab in a late-stage study. The company is now focusing on earlier-stage assets and partnered programs with Novo Nordisk, Roche, and Bristol Myers Squibb. Prothena also undertook a significant workforce reduction to manage operating costs.
(PRTA) Movement Within Algorithmic Entry Frameworks
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using algorithmic entry frameworks. It highlights strong near-term sentiment potentially challenging persistent mid and long-term weakness and identifies support being tested. The analysis suggests an exceptional 147.5:1 risk-reward setup targeting a 34.5% gain, providing specific institutional trading strategies for long and short positions, along with multi-timeframe signal analysis.
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Prothena Corporation plc announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of U.S. financial markets. This will be followed by a live audio conference call at 4:30 PM ET. A replay of the call will be available on the company's website.
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Prothena Corporation plc announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the U.S. financial markets close. This will be followed by a live audio conference call at 4:30 PM ET, accessible via the company's website and dial-in numbers. A replay will be available for 90 days on the website and via dial-in until February 26, 2026.
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Prothena Corporation plc (NASDAQ:PRTA) announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of U.S. financial markets. This announcement will be followed by a live audio conference call at 4:30 PM ET. The company, a late-stage clinical biotechnology firm, specializes in protein dysregulation expertise for neurodegenerative and rare peripheral amyloid diseases.
Prothena Corporation plc (NASDAQ:PRTA) Given Average Rating of "Hold" by Analysts
Prothena Corporation plc (NASDAQ:PRTA) has received a consensus "Hold" rating from twelve analysts, with an average 12-month price target of $25.60. The biotechnology company recently reported a quarterly EPS miss of -$0.67 and revenue miss of $2.42 million, and remains unprofitable. Institutional investors hold a significant portion of the stock, with 97.08% ownership.
How (PRTA) Movements Inform Risk Allocation Models
This article analyzes Prothena Corporation Plc (PRTA) using AI models to inform risk allocation. It highlights a near-term weak sentiment that may signal a resumption of long-term weakness, with support currently being tested. The analysis provides specific trading strategies—position trading, momentum breakout, and risk hedging—along with multi-timeframe signal analysis and risk-reward setups for PRTA.
Trading Systems Reacting to (PRTA) Volatility
This article from Stock Traders Daily discusses AI-generated trading strategies for Prothena Corporation Plc (NASDAQ: PRTA) based on current volatility. It outlines both short and long trading opportunities with specific entry, target, and stop-loss points across different time horizons, highlighting a potential near-term shift in sentiment and a strong short setup. The analysis provides signals and risk parameters for institutional trading strategies.
Prothena announces board of directors update
Prothena has announced an update to its board of directors. Further details concerning the changes were not provided in this brief announcement.
How Prothena Corporation Plc (PRTA) Affects Rotational Strategy Timing
The article analyzes Prothena Corporation Plc (PRTA) and its impact on rotational strategy timing, indicating a near-term neutral sentiment that suggests a pause in mid and long-term weakness. It highlights an exceptional risk-reward setup with a target gain of 39.5% versus a 0.3% risk, and provides three distinct AI-generated trading strategies tailored for different risk profiles and holding periods, including position, momentum breakout, and risk hedging strategies.
Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Rating of "Hold" from Brokerages
Prothena Corporation plc (NASDAQ:PRTA) has received a consensus "Hold" rating from twelve brokerage firms, with an average one-year price target of $25.60. This recommendation comes despite the company missing recent quarterly earnings and revenue estimates. The stock's performance metrics and institutional ownership details are also highlighted.
EX-99.1
Prothena announced that Novo Nordisk will advance coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with cardiomyopathy. Novo Nordisk successfully completed a Phase 2 trial and expects to initiate the Phase 3 program in 2025. Prothena is eligible to receive a clinical milestone payment upon meeting prespecified enrollment criteria in the Phase 3 trial, as part of an agreement that could total up to $1.2 billion in milestones.
(PRTA) and the Role of Price-Sensitive Allocations
This article provides an in-depth analysis of Prothena Corporation Plc (NASDAQ: PRTA), highlighting a mid-channel oscillation pattern and a near-term neutral sentiment amidst mid and long-term weakness. It outlines specific institutional trading strategies across different risk profiles, including position trading, momentum breakout, and risk hedging. The analysis also details AI-generated signals, support, and resistance levels for various time horizons.
Squarepoint Ops LLC Takes $1.27 Million Position in Prothena Corporation plc $PRTA
Squarepoint Ops LLC acquired a new stake worth approximately $1.27 million in Prothena Corporation plc (NASDAQ:PRTA) during the second quarter, representing 0.39% ownership. Despite several analysts raising price targets, the stock currently holds a consensus "Hold" rating with an average target of $25.60. Prothena, a clinical-stage biotech focusing on neurodegenerative diseases, reported negative EPS and missed revenue estimates in its last quarter, with its stock trading around $9.21.
Prothena announces board of directors update
This article is empty and contains no content about Prothena's board of directors update. It is stated as "MSN" but provides no further details.
Paula Cobb steps down from Prothena’s board to join Manifold Bio
Paula Cobb has resigned from Prothena Corporation's board of directors after six years to become the Chief Operating Officer at Manifold Bio. Prothena, a biotech company developing treatments for neurodegenerative diseases, acknowledged Cobb's strategic contributions, and its shares have significantly surged in the past six months despite a year-to-date decline. Analysts maintain high price targets for Prothena, citing its undervalued status and promising pipeline.
Prothena Board Member Paula Cobb Resigns
Paula Cobb has resigned from Prothena Corporation plc’s Board of Directors, effective December 31, 2025, with no reported disagreements with the company. Prothena (PRTA) stock currently holds a Hold rating from analysts with a $10.50 price target, and TipRanks’ AI Analyst, Spark, rates PRTA as Neutral due to financial challenges despite some positive technical momentum. The company faces concerns regarding profitability and valuation but has a positive outlook for financial flexibility after a recent corporate event.
Paula Cobb steps down from Prothena’s board to join Manifold Bio
Paula Cobb has resigned from Prothena's board of directors after six years to become the Chief Operating Officer at Manifold Bio. Prothena, a biotech company focused on neurodegenerative and rare peripheral amyloid diseases, acknowledged Cobb's significant contributions while reporting that its shares have surged by 103.75% in the last six months. The company continues to advance its clinical pipeline, with recent analyst upgrades and promising preclinical and trial data for its therapeutic candidates.
Birchview Capital LP Has $2.74 Million Stock Holdings in Prothena Corporation plc $PRTA
Birchview Capital LP increased its stake in Prothena Corporation plc (NASDAQ:PRTA) by 35.5% in the second quarter, bringing its total holdings to 451,019 shares valued at $2.74 million. Other institutional investors also adjusted their positions in the biotechnology company. Analysts have issued varied ratings for Prothena, with an average "Hold" rating and a $25.27 price target.
Prothena Board Member Paula Cobb Resigns
Paula Cobb has announced her resignation from Prothena Corporation plc's Board of Directors, effective December 31, 2025. Her departure is not due to any disagreements with the company's operations. Prothena's stock (PRTA) is currently rated as a Hold by analysts with a $10.50 price target, and TipRanks' AI Analyst also rates it Neutral due to financial challenges despite some positive technical indicators.
Prothena Announces Board of Directors Update
Prothena Corporation plc announced that Paula Cobb will step down from its Board of Directors to join Manifold Bio as Chief Operating Officer after six years of service. Daniel G. Welch, Chair of Prothena’s Board, thanked Ms. Cobb for her significant contributions to the Company’s vision and strategy. Prothena, a late-stage clinical biotechnology company, will now have 8 Directors on its board.
Prothena Announces Board of Directors Update
Prothena Corporation plc announced that Paula Cobb is stepping down from its Board of Directors to become Chief Operating Officer at Manifold Bio. Ms. Cobb served on Prothena's board for six years, contributing significantly to the company's vision and strategy. Her departure leaves Prothena with 8 Directors on its board.
Daily Penny Alerts - Prothena Announces Board of Directors Update
Prothena Corporation plc announced that Paula Cobb is stepping down from its Board of Directors to become Chief Operating Officer at Manifold Bio. Ms. Cobb served on Prothena's board for six years, contributing significantly to the company's long-term vision and strategy. The company expressed gratitude for her contributions and wished her success in her new role, while Cobb affirmed her confidence in Prothena's strategic vision.
Prothena (NASDAQ: PRTA) director Paula Cobb departs board, leaving 8 members
Prothena Corporation plc announced that Paula Cobb is stepping down from its Board of Directors to become Chief Operating Officer at Manifold Bio. Ms. Cobb served on Prothena's board for six years, contributing significantly to the company's vision and strategy. Her departure leaves Prothena with eight directors on its board.
Liquidity Mapping Around (PRTA) Price Events
An analysis of Prothena Corporation Plc (NASDAQ: PRTA) indicates near-term weak sentiment despite mid-term strength within a broader long-term weak bias. The stock shows an exceptional 105.0:1 risk-reward short setup, targeting a 29.8% downside against a 0.3% risk. AI models have generated three distinct trading strategies for PRTA including position trading, momentum breakout, and risk hedging strategies, each with specific entry, target, and stop loss points.
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
Prothena Corporation plc announced a poster presentation at Neuroscience 2025 highlighting preclinical data for its TDP-43 CYTOPE® program. The data demonstrates the CYTOPE technology's potential as a novel modality for delivering large molecules into cells, effectively targeting intracellular disease pathways. Systemically-administered TDP-43 CYTOPE significantly reduced intracellular TDP-43 pathology and associated RNA dysregulation in an ALS mouse model and human-derived neuronal cell lines.
Prothena (NASDAQ: PRTA) Highlights TDP-43 CYTOPE ALS Preclinical Data on Pathology
Prothena Corporation plc announced preclinical data for its TDP-43 CYTOPE program, demonstrating the technology's potential for delivering large molecules into cells to target intracellular disease pathways in ALS. The data, presented at Neuroscience 2025, showed that systemically-administered TDP-43 CYTOPE rapidly targets and reduces intracellular TDP-43 pathology in both mouse models and human-derived neuronal cell lines, addressing key pathogenic features of TDP-43 proteinopathies. This highlights the innovative approach for treating neurodegenerative diseases.
Prothena stock price target raised to $19 from $11 at Citizens
Citizens has raised its price target for Prothena (NASDAQ:PRTA) to $19 from $11, maintaining a Market Outperform rating, due to advancements in partnered programs, especially the reintroduction of prasinezumab for Parkinson's disease. The firm anticipates Prothena could receive up to $105 million in clinical milestone payments by 2026 and highlighted the potential of its discovery engine and earlier-stage pipeline. Other analysts, H.C. Wainwright and Piper Sandler, have also increased their price targets to $30 and $36, respectively, reflecting growing interest in Prothena's pipeline and its potential impact on serious diseases.
Citizens Raises Price Target for Prothena Corp (PRTA) to $19.00
Citizens analyst Jason Butler has increased the price target for Prothena Corp (PRTA) from $11.00 to $19.00, while maintaining a "Market Outperform" rating. This adjustment reflects a 72.73% increase and follows various other analyst adjustments, highlighting differing perspectives on the stock's potential. Prothena Corp is a clinical biotechnology company focused on neurodegenerative and rare amyloid diseases.
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
Prothena Corporation plc (NASDAQ:PRTA) announced a poster presentation at Neuroscience 2025 detailing preclinical data on its TDP-43 CYTOPE® program. The data demonstrates the CYTOPE® technology's potential as a novel modality for delivering large molecules into cells, specifically targeting intracellular TDP-43 pathology related to ALS and other proteinopathies. Systemically-administered TDP-43 CYTOPE® was shown to rapidly distribute to the brain and periphery, reduce intracellular TDP-43 pathology in an ALS mouse model, and address associated RNA dysregulation in human neuronal cell lines.
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Brokerages
Prothena Corporation plc (NASDAQ:PRTA) has received an average "Hold" rating from ten brokerages, with an average 12-month price target of $25.78. The company recently missed earnings expectations, reporting a ($0.67) EPS against a ($0.60) estimate and $2.42M in revenue against $6.64M expected. Despite this, institutional investors own a significant portion of the stock, with several funds increasing their stakes.
DCF Advisers LLC Lowers Stock Position in Prothena Corporation plc $PRTA
DCF Advisers LLC reduced its stake in Prothena Corporation plc (NASDAQ:PRTA) by 19.7% in the second quarter, selling 38,500 shares and ending with 156,500 shares valued at $950,000. This comes as Prothena reported weak quarterly results with an EPS miss of ($0.67) against an estimated ($0.60) and revenue of $2.42 million versus an expected $6.64 million, leading to a deeply negative net margin. The stock currently trades around $10.48, and analysts have a mixed "Hold" rating with an average price target of $25.78.
Prothena Corporation plc $PRTA Position Lessened by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. significantly reduced its stake in Prothena Corporation plc (NASDAQ:PRTA) by 79.3% in Q2, selling 72,586 shares and retaining 18,896 shares valued at $115,000. This comes as Prothena reported a quarterly earnings and revenue miss, demonstrating deep unprofitability. Despite mixed analyst ratings, with an average "Hold" and target price of $25.78, the stock trades near $10.48.
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
Novo Nordisk's Coramitug Phase 2 trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) showed promise in reducing NT-proBNP, a heart failure biomarker. The antibody, acquired from Prothena, was well tolerated, with a 60 mg/kg dose significantly reducing NT-proBNP levels. Novo Nordisk has initiated a Phase 3 trial, and Prothena is eligible for further milestone payments.
Prothena to Report Third Quarter 2025 Financial Results on November 6
Prothena Corporation plc announced it will report its third quarter and first nine months of 2025 financial results on Thursday, November 6, 2025, after the close of U.S. financial markets. The company, a late-stage clinical biotechnology firm focusing on protein dysregulation, consistent with past practice, will not host a conference call for this release.
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
Prothena Corporation plc reported its third-quarter and first nine months of 2025 financial results, highlighting significant advancements in its clinical pipeline through partnerships. Key developments include Roche initiating a Phase 3 trial for prasinezumab in Parkinson's, Novo Nordisk starting a Phase 3 trial for coramitug in ATTR amyloidosis with cardiomyopathy, and Bristol Myers Squibb obtaining Fast Track designation for BMS-986446 for Alzheimer’s disease. The company also announced plans for an Extraordinary General Meeting to seek shareholder approval for a share capital reduction to support a potential share redemption program in 2026.
Prothena Corporation plc (PRTA): A Bull Case Theory
Prothena Corporation plc (PRTA) is presented as a bullish investment opportunity given its transition to a capital-rich wind-down phase, with most of its pipeline partnered to major pharmaceutical companies like Roche and Novo. The company's value is driven by potential milestones and royalties from these programs, which could exceed its current enterprise value, alongside a substantial net cash position intended for capital return to shareholders. This strategy, coupled with a recent workforce reduction, positions PRTA as a high-risk/high-reward investment focused on late-stage biotech assets.
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
Prothena announced that Novo Nordisk plans to advance coramitug (formerly PRX004), an amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with cardiomyopathy in 2025. Following Novo Nordisk's successful Phase 2 trial, Prothena is eligible for a clinical milestone payment upon meeting prespecified enrollment criteria in the Phase 3 clinical trial. This development highlights the potential for coramitug to address a significant unmet medical need for patients with this condition.
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
Prothena announced that Novo Nordisk plans to advance coramitug (formerly PRX004), an amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy (ATTR-CM), into Phase 3 development in 2025. Prothena is eligible for a clinical milestone payment once specific enrollment criteria are met in the Phase 3 trial. This decision follows Novo Nordisk's successful completion of a Phase 2 trial and highlights the ongoing unmet need for effective treatments for ATTR-CM.
Peninsula biotech will cut half its workforce, but partner takes Parkinson's drug into late-stage trial
Prothena, a Peninsula-based biotech company, is set to cut half of its workforce, impacting 91 jobs including several executives, despite its partner Roche advancing a Parkinson's drug into a late-stage clinical trial. This move suggests strategic shifts for Prothena as its lead Parkinson's therapeutic progresses with a larger pharmaceutical partner. The job cuts span various departments such as clinical operations and marketing.
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Prothena announced that its partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease. This decision is based on promising data from the Phase IIb PADOVA study and ongoing open-label extensions, which suggest a potential clinical benefit in slowing disease progression. Prasinezumab aims to address the significant unmet need for disease-modifying treatments in Parkinson's, a condition affecting over 10 million people globally.
Prothena’s Phase III trial for AL amyloidosis treatment misses endpoint
Prothena Corporation announced that its Phase III AFFIRM-AL trial for birtamimab, an AL amyloidosis treatment, failed to meet its primary endpoint of time to all-cause death. Consequently, the company will discontinue the therapy's development and halt the open-label extension of the trial, despite the drug being generally safe and well-tolerated. Prothena plans to minimize operating costs and review business options, while continuing to focus on its pipeline for neurodegenerative and rare peripheral amyloid conditions.
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
Prothena Corporation plc announced its financial results for the first quarter of 2025, reporting a net loss of $60.2 million and a total revenue of $2.8 million. The company highlighted several key clinical milestones, including anticipated topline results in Q2 2025 for the Phase 3 AFFIRM-AL clinical trial of birtamimab and multiple clinical readouts for PRX012 in Alzheimer's disease starting mid-2025. Prothena also provided updates on its partnered programs for Parkinson's disease and ATTR amyloidosis, maintaining its full-year 2025 financial guidance for net cash used in operating and investing activities.
Prothena Announces Leadership Team Updates
Prothena Corporation plc announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer, taking over leadership of clinical development and medical functions. Hideki Garren, M.D., Ph.D., the former Chief Medical Officer, is departing to pursue an opportunity at a large pharmaceutical company. Dr. Swanson brings over 20 years of industry experience, including his work on the lecanemab program for Alzheimer's disease at Eisai, Inc.
